






SUPPLEMENTARY FIGURES




Supplementary Figure 1. Association of tocilizumab with all-cause mortality (A) all RCTs (B) study type (C) type of control (D) Forest plot without the RECOVERY trial.




Supplementary Figure 2. Association of tocilizumab with all-cause mortality (A) funnel plot to assess the publication bias of the meta-analysis (B) sensitivity analysis.



Supplementary Figure 3. Association of tocilizumab with discharge (A) all RCTs (B) study type.



Supplementary Figure 4. Association of tocilizumab with patients of serious adverse events.



Supplementary Figure 5. Association of tocilizumab with secondary infections risk (A) all RCTs (B) peer-reviewed (C) type of control.